Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Receivables (2016 - 2025)

CytomX Therapeutics' Change in Receivables history spans 12 years, with the latest figure at $384000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables rose 254.22% year-over-year to $384000.0; the TTM value through Dec 2025 reached -$1.1 million, down 231.31%, while the annual FY2025 figure was -$1.1 million, 231.31% down from the prior year.
  • Change in Receivables reached $384000.0 in Q4 2025 per CTMX's latest filing, up from -$240000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $34.2 million in Q4 2022 to a low of -$34.9 million in Q1 2023.
  • Average Change in Receivables over 5 years is $60750.0, with a median of $116500.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: surged 35368.04% in 2022, then crashed 15141.38% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$97000.0 in 2021, then soared by 35368.04% to $34.2 million in 2022, then plummeted by 97.04% to $1.0 million in 2023, then crashed by 124.58% to -$249000.0 in 2024, then skyrocketed by 254.22% to $384000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Change in Receivables are $384000.0 (Q4 2025), -$240000.0 (Q3 2025), and -$87000.0 (Q2 2025).